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ABSTRAK
Latar belakang: DLBS1033 adalah fraksi protein bioaktif yang diekstraksi dari Lumbricus rubellus, dan dari 
studi in vitro diketahui memiliki aktivitas fibrinogenolitik, fibrinolitik dan antiagregasi. Waktu paruh obat dalam 
plasma merupakan parameter yang penting dalam menghitung dosis obat. Studi ini dilakukan untuk mengevaluasi 
waktu paruh biologis DLBS1033 melalui pengukuran kadar plasmin-antiplasmin complex (PAP complex). PAP 
complex adalah senyawa hasil proses fibrinolisis yang stabil dan inaktif. Metode: desain studi ini adalah uji klinik 
terbuka pada subyek dewasa sehat. Subyek dibagi menjadi dua kelompok, kelompok yang mendapatkan dosis 
tunggal (diberi obat 3 x 490 mg) dan kelompok yang mendapatkan dosis berulang hingga mencapai steady state 
(diberi obat 3 x 490 mg/hari selama 3 hari). Sampel darah untuk pemeriksaan konsentrasi PAP complex diambil 
pada jam ke-0 (sebelum pemberian obat pada kelompok dosis tunggal), jam ke-0,5, 1, 1,5, 2, 3, 4, 6, 8, 10, 12, dan 
24. Parameter keamanan yang diperiksa pada penelitian ini adalah kreatinin, prothrombin time (PT), activated 
partial thromboplastin time (aPTT), SGOT, dan SGPT. Hasil: waktu paruh biologis DLBS1033 dihitung berdasarkan 
rerata kadar PAP complex pada tiap waktu pengambilan sampel darah di tiap kelompok. Pada kelompok dosis 
tunggal, rerata tertinggi konsentrasi PAP complex tercapai sebelum pemberian obat. Hasil ini menunjukkan bahwa 
aktivitas DLBS1033 tidak bermakna ketika diberikan sebagai dosis tunggal. Pada keadaan steady state, konsentrasi 
PAP complex meningkat dalam 2 jam setelah pemberian obat terakhir. Waktu paruh biologis DLBS1033 adalah 
8,6 jam. Pada penelitian ini tidak didapatkan hasil laboratorium yang bermakna dan kejadian tidak diinginkan 
yang serius. Kesimpulan: pada penelitian ini disimpulkan bahwa efek fibrinolitik DLBS1033 dapat diukur pada 
keadaan steady state. Waktu paruh biologis DLBS1033 pada kelompok steady state adalah 8,6 jam. Tidak ditemukan 
kejadian tidak diinginkan yang serius pada kedua kelompok subyek.
Kata kunci: Lumbricus rubellus, fibrinolitik, plasmin-antiplasmin complex, waktu paruh biologis, DLBS1033.
ABSTRACT
Background: DLBS1033 is a bioactive protein fraction extracted from Lumbricus rubellus, with fibrinogenolytic, 
fibrinolytic and anti-aggregation activities reported in an in vitro study. Plasma half-life is an important parameter 
to calculate its dose. This study was conducted to evaluate the biological half-life of DLBS1033 by measuring serial 
plasmin-antiplasmin (PAP) complex. PAP complex is a stable and inactive compound as a result of fibrinolysis 
process. Methods: this was an open-label clinical trial in healthy adult subjects. Subjects were divided into two 
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groups to receive single dose drugs (received 3 x 490 mg) or repeated administration until steady state conditions 
(3 x 490 mg/day for 3 days). Blood samples for PAP complex measurement were collected at time 0 (before drug 
administration for single dose group), then at 0.5, 1, 1.5, 2, 3, 6, 8, 10, 12, and 24 hours after drug administration. 
Safety parameters used in this study were creatinine, prothrombin time (PT), activated partial thromboplastin time 
(aPTT), SGOT, and SGPT. Results: the biological half-life of DLBS1033 was calculated based on the mean of PAP 
complex concentration on each time sampling. In single dose group, the highest mean of PAP complex concentration 
was reached before drug administration. Our result showed that the activity of DLBS1033 could not be determined 
after single dose administration. In steady state condition, the PAP complex concentration increase in 2 hours 
after last drug administration. The biological half-life of DLBS1033 was 8.6 hours. There were no significant 
safety findings on all laboratory parameters and no serious adverse events. Conclusion: it is concluded that the 
fibrinolytic effects of DLBS1033 can be measured in steady state condition. The biological half-life of DLBS1033 
in steady state condition was 8.6 hours. There were no serious adverse events on two groups of subjects.
Keywords: Lumbricus rubellus, fibrinolytic, plasmin-antiplasmin complex, biological half-life, DLBS1033.
INTRODUCTION
Enzyme from earthworm alimentary tract 
has been known for its ability to dissolve 
fibrin. In 1991, Mihara et al1 extracted enzyme 
from alimentary tract of Lumbricus rubellus, 
which consist of six isoenzyme serine protease 
that collectively named as lumbrokinase.1 
From several studies, it has been known that 
lumbrokinase has fibrinolytic, fibrinogenolytic, 
antiinflammatory activities, and could reduce 
platelet aggregation.2-4
The efficacy of oral lumbrokinase has been 
investigated in some clinical trials. Jin et al5 
conducted a study on 51 cerebral infarct subjects 
who was given oral lumbrokinase for 28 days. 
They concluded that mechanism of lumbrokinase 
are inhibit intrinsic coagulation pathway and 
activate fibrinolytic pathway by increasing t-PA 
activity.5 Fibrinolytic activity was also concluded 
by Rey6, who conducted a study on 28 diabetic 
foot ulcer subjects, which were given three times 
500 mg lumbrokinase/placebo per day (n=14) 
for seven days. In the treatment group, D-dimer 
was increased.
From many clinical trials, it is concluded that 
effects of lumbrokinase can be seen after several 
days. It is different with intravenous fibrinolytic 
enzyme which effects can be seen immediately 
after used. Therefore oral lumbrokinase could not 
replace the function of an intravenous fibrinolytic 
enzyme which is used on acute thrombosis. 
Oral lumbrokinase might be used for secondary 
prevention after acute thrombosis, such as 
myocardial infarct and stroke.
DLBS1033 is bioactive protein fraction 
which is extracted from Lumbricus rubellus 
earthworm. This earthworm comes from 
Pengalengan, West Java, Indonesia. DLBS1033 
possesses eight major proteins with molecular 
weight below 100 kDa, so it is named as 
Lumbricus Low Molecular Weight Proteins 
(LLP).2 This enzyme can be transported to the 
bloodstream via intestinal epithel.7 As a drug that 
consists of serine protease enzyme, it is suspected 
that the mechanism of action of lumbrokinase, 
especially as fibrinolytic and antithrombotic. 
In vitro study by Trisina et al2 showed that 
DLBS1033 has fibrinogenolytic activities on 
fibrinogen α, β, and γ chain, decreasing platelet 
aggregation and prolong clotting time.2
Plasma half-life is a very important parameter 
to calculate the dose and interval administration 
of DLBS1033. The active fraction of DLBS1033 
in plasma could not be measured since the active 
isoenzyme is still unknown. Therefore, the aim 
of this study was to evaluate the biological 
half-life of DLBS1033 by measuring serial 
plasmin-antiplasmin (PAP) complex. PAP 
complex is a stable and inactive compound as 
a result of fibrinolysis process which is started 
with activation of plasminogen to plasmin. This 
activation will produce free plasmin that binds 
to antiplasmin and becomes PAP complex.8-10
Anggi Gayatri                                                                                                         Acta Med Indones-Indones J Intern Med
210
METHODS
This study was an open label clinical 
trial, which was done at Pharmacology and 
Therapeutic Department and Clinical Pathologic 
Department of Faculty of Medicine Universitas 
Indonesia, Cipto Mangunkusumo Hospital in 
July - December 2012. The study drug was enteric 
coated DLBS1033 tablet, which contained 490 
mg bioactive protein fraction; and produced by 
PT Dexa Medica, Tangerang, Indonesia.
Subjects
This trial was conducted on 14 healthy 
male subjects. Subjects were considered 
healthy if vital signs, physical examination, and 
hematological parameters was within normal 
range. Other inclusion criteria were male, 18-
55 years old, body mass index of 18-25 kg/m2, 
gave written informed consent and have PAP 
complex level between 0-514 ng/mL. Exclusion 
criteria were subjects with cardiovascular 
disease, diabetes mellitus, and dyslipidemia, 
creatinine serum (normal 0,5-1,5 mg/dL) of more 
than 1.5 x ULN (upper limit normal), SGOT 
(normal 10-35 Unit) and SGPT (normal 10-40 
Unit) of more than 3 x ULN, blood pressure 
≥ 140/90 mmHg, fasting blood glucose  >126 
mg/dL, alcoholic patients, those who took any 
medications (including traditional medicines, 
supplements, and vitamins) one week before the 
study, had bleeding history with unclear etiology, 
hemoglobin level <10 g/dL, thrombocyte count 
<100.000/µL and a heavy smoker (Brinkman 
Index >600). Brinkman index was calculated 
as the product of the number of tobacco smoke 
per year. Brinkman index was calculated as 
tobacco smoke per day times number of year of 
active consumption. Based on Brinkman index, 
smokers was divided into two groups, heavy 
smoker (Brinkman index ≥ 600) and light smoker 
(Brinkman index <600).11
Subjects was dropped out if there were 
hypersensitivity reactions because of study 
medicine, subject were not taking the studied 
medicine as instructed, or taking any other drugs 
when they were in this trial without permission 
from investigator. Subjects were divided into two 
groups, one group for single dose administration 
and one group for steady state condition.
Ethical Approval and Informed Consent
The Committee of Medical Research 
Ethics of Faculty of Medicine, University of 
Indonesia has reviewed the study protocol and 
issued the approval letter on 25th July 2011. 
Consent and signed informed consent to enter 
the study was obtained from each participant 
after a full explanation and information leaflet 
has been given. This study was also registered 
at  clinicaltrials.gov NCT01905878.
Study Procedure
Potential subjects were invited to receive 
explanation of the study. After informed consent 
form had been signed, investigator collected 
the subject’s medical history, data on alcohol 
consumption habit, data on medication that had 
been taken seven days before study (including 
traditional medicine and supplement), smoking 
habit, bleeding history with unknown etiology, 
and calculated the subject’s body mass index 
based on body weight and height measurement. 
Subjects also undergone a clinical assessment 
including vital signs, and laboratory assessment 
of routine hematology, fasting blood glucose, liver 
function test (SGOT and SGPT), renal function 
test (serum creatinine), thrombocyte aggregation 
and PAP complex.
Procedure
Eligible subjects were randomized to receive 
single dose (3 x 490 mg) or repeated dose until 
steady state conditions (3 x 490 mg/day for 3 
days).
The eligible subjects of single dose group 
were instructed to come to study site on the 
scheduled day. Blood samples were collected 
to assess PAP complex concentration , serum 
creatinine, SGOT, SGPT, PT (prothrombin time) 
and aPTT (activated partial thromboplastin time). 
Subjects were instructed to take three tablets of 
enteric coated DLBS1033 in front of investigator 
with 240 mL of water. Blood samples were 
collected on 30 minute, 60 minute, 90 minute, 2 
hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 
hour, and 24 hour to evaluate serial PAP complex.
The eligible subjects of steady state condition 
group instructed to come to study site on the 
scheduled day (day 1 and day 4). On day 1 
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blood samples collected to assess PAP complex 
concentration, serum creatinine, SGOT, SGPT, 
PT, and aPTT. Subjects instructed to take one 
tablet enteric coated of DLBS1033 with 240 mL 
of water in front of the investigator. Study drug 
package (consist of 8 tablets) dispensed to the 
subjects at day-1, and they were instructed to 
take the drug three times daily 30 minutes before 
meals. Subjects also were instructed to record 
any adverse events and concomitant medication 
prescribed in diary card. Subjects had to take 
the drug for three days (day 1, 2, and 3). On 
day 4, subjects were instructed to come to study 
site. Blood samples were collected at time 0, 30 
minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 
hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 
hour to evaluate serial PAP complex.
All subjects were asked to stay for two 
nights in PT. Equilab International Laboratory 
staying room. Subjects were only permitted to 
eat food from investigator and not permitted to 
smoke. Subjects were requested to fast for 10 
hours before drug administration for single dose 
group and prior plasma sampling for steady state 
group. All subjects were undergone a clinical 
assessment including vital signs and the presence 
of adverse events at the time of blood sampling. 
Any adverse events were recorded on case report 
form (CRF).
Statistical Analysis
Demographic, clinical, and laboratory 
data were recorded in case report form for 
each subject. Adverse events were evaluated 
by investigator and recorded in adverse event 
Table 2. Laboratory parameters of study subjects at 
baseline
Variables
Mean (SD)
Single dose 
group (n=7)
Steady state 
group (n=7)
Hemoglobin (g/dL) 15.5 (1.14) 14.9 (0.77)
Hematocrit (%) 45.3 (3.03) 44 (2.30)
Thrombocyte (/mL) 266 714.3 (50 135.53)
273 714.3 
(56 870.36)
SGOT (U/L) 22.9 (7.60) 23.4 (3.91)
SGPT (U/L) 17.3 (14.81) 21.4 (11.84)
Serum creatinine (mg/dL) 0.9 (0.07) 0.9 (0.11)
Fasting blood glucose  
(mg/dL) 74.9 (8.43) 74.3 (9.43)
PAP complex (ng/mL) 54.2 (9.94) 70.7 (20.78)
Thrombocyte aggregation 
(%) 78 (8.89) 71.9 (10.67)
Table 1. Demographic characteristics of study subjects
Variables
Mean (SD)
Single dose 
group (n=7)
Steady state 
group (n=7)
Age (years) 23.8 (4.78) 32.4 (10.69)
Height (cm) 166 (6.11) 161 (5.07)
Weight (kg) 55.1 (6.01) 55.4 (4.72)
Body mass index (kg/m2) 20 (2.15) 21.5 (2.31)
Brinkman index 28.3 (25.15) 34.7 (47.68)
form in case report form. Serial PAP complex 
concentrations were analyzed as descriptive data. 
RESULTS
The result of demographic and laboratory 
screening were shown on Table 1 and Table 2. 
Table 3. PAP complex (ng/mL) after single dose DLBS1033 administration (N = 7)
Time of blood sampling  (hours) 1 2 3 4 5 6 7 Mean
0 60.59 63.24 58.24 51.47 69.56 44.71 56.32 57.73
0.5 42.21 52.35 58.38 39.26 56.62 45.88 59.12 50.55
2 35.44 42.5 58.97 43.24 53.24 31.76 53.09 45.46
3 41.47 56.18 31.91 27.79 44.85 25.44 42.06 38.53
4 26.62 32.79 31.91 30.44 32.94 34.12 88.09 39.56
5 30 47.06 47.21 31.76 24.12 12.5 36.18 32.69
6 16.62 28.68 37.94 30.15 26.03 10.88 13.97 23.47
8 9.85 33.09 18.24 16.91 21.32 28.68 20.44 21.22
10 15.59 16.76 13.68 16.91 13.82 17.94 21.03 16.53
12 8.53 8.24 12.21 17.21 24.12 9.26 9.12 12.67
14 25.29 11.47 22.94 15.29 27.35 9.56 4.71 16.66
24 2.65 15.74 15 7.94 11.91 10.88 15.88 11.43
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Biological half-life of DLBS1033 in Single 
Dose Administration
Serial PAP complex parameter after single 
dose administration of DLBS1033 were shown 
on Table 3.
The highest mean of serial PAP complex (y) 
was 57.73 ng/mL, and was reached prior to drug 
administration. This result meant that the activity 
of DLBS1033 after single dose administration 
was too small to determine.
Biological Half-life of DLBS1033 in Steady 
State Condition
From data in vivo trial, the half life of 
DLBS1033 is 8 hours. It was predicted that 3 
x 490 mg DLBS1033 per day for three days 
administration was enough to reach steady state 
condition. The result of serial PAP complex 
concentration from steady state group is shown 
on Table 4.
The biological half-life of DLBS1033 was 
calculated based on mean of PAP complex on 
each time sampling from seven subjects. Figure 
1 showed the mean PAP complex on steady state 
condition of DLBS1033.
In steady state condition, the PAP complex 
concentration increased in 2 hours after last drug 
administration. From Figure 1, the linier equation 
of mean serial PAP complex was y = - 2,9087x + 
54,556. The highest mean of serial PAP complex 
(y) was 59,18 ng/mL. That value become 29,59 
ng/mL in:
y = - 2.9087x + 54.556
29.59 ng/mL = - 2.9087x + 54.556
x = 8.6 hours
In steady state condition, the biological half 
life of DLBS1033 was 8.6 hours.
Safety Parameters
There were five laboratory parameters that 
measured as safety parameters i.e. PT, aPTT, 
SGOT, SGPT, and creatinine serum. There 
were no significant findings on all laboratory 
parameters, only four adverse events from 14 
subjects (Table 5) and no serious adverse events 
in this study.
Table 4. PAP complex (ng/mL) concentration on steady state condition of DLBS1033 (N = 7)
Time of blood sampling  (hours) 8 9 10 11 12 13 14 Mean
0 46.47 55.44 57.79 76.62 46.62 54.85 72.06 58.55
0,5 49.41 55.59 52.21 60.74 56.32 43.53 53.58 53.07
2 26.91 55 42.35 54.26 57.65 47.94 130.15 59.18
3 21.18 39.41 30 42.79 31.32 41.91 70.74 39.62
4 42.5 63.53 36.47 46.03 39.41 22.79 61.47 44.60
5 33.68 34.41 45.59 41.62 19.26 23.68 54.41 36.09
6 29.56 23.82 30.29 46.03 37.5 34.85 55.44 36.78
8 17.65 18.97 26.03 17.35 17.65 30.29 46.32 24.89
10 9.71 13.38 17.21 17.35 10.59 23.97 28.38 17.23
12 16.62 11.18 17.21 28.68 23.97 21.91 32.06 21.66
14 10.74 14.85 12.65 23.68 20.74 8.38 26.76 16.83
24 9.71 10.44 8.38 14.41 19.12 30.74 87.5 25.76
Figure 1. Mean of serial PAP complex in each time sampling 
of 7 subjects from steady state condition of DLBS1033 group
Table 5. Adverse events of single dose and steady state 
subject group (N = 14)
No. Adverse events
No of subjects
Single dose 
group
No of subjects
Steady state 
group
1 Headache 1 -
2 Dizziness 1 -
3 Myalgia 1 1
Total 3 1
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DISCUSSION
DLBS1033 is a lumbrokinase extract 
obtained from Lumbricus rubellus that possesses 
eight isoenzymes. Similar to other lumbrokinase, 
we predict that the mechanism of action of 
DLBS1033, especially as plasminogen activator. 
This prediction is supported by the result 
in an in vitro study by Trisina et al2, which 
showed that DLBS1033 has fibrinogenolytic 
activities, decreasing platelet aggregation 
and prolong clotting time. As a plasminogen 
activator, DLBS1033 will activate plasminogen 
to be plasmin. The free-plasmin will bind to 
antiplasmin and form plasmin-antiplasmin 
complex (PAP complex). The PAP complex 
concentration was used as a fibrinolytic parameter 
on this study.9,10
Coagulation and f ibrinolysis  are a 
physiological process which is controlled by 
several factors. These two processess control 
our blood fluidity. Fibrinolysis process starts 
when fibrins are deposited as a product of 
coagulation process. Fibrin regulates its own 
degradation by bind to plasminogen and tPA. 
This binding activate tPA to convert plasminogen 
to plasmin. Once formed, plasmin cleaves 
fibrin.9,13 Plasmin binding-fibrin will degrade 
fibrin clot to be fibrin degradation product, and 
degrade cross-linked fibrin to be D-dimer.8,9 
Free plasmin will bind to antiplasmin and 
become plasmin-antiplasmin complex (PAP 
complex) which is stable and inactive.10 Normal 
concentrations of PAP complex are different 
among individuals. It depends on some factors, 
such as inflammation; however, high level of PAP 
complex concentration is not directly linked to 
inflammation.14
On single dose of DLBS1033 (Table 3), 
the PAP complex was not increased after drug 
administration. The highest PAP complex 
concentration was reached before drug 
administration. This result indicated that the 
activity of DLBS1033 was too small to detect 
after single dose administration. DLBS1033 is 
an oral drug, and it needs to be absorbed and 
might pass the first metabolism process before 
exerting its effect.7 It might need few hours 
to reach steady-state condition to measure the 
DLBS1033 fibrinolytic activity. The biological 
half-life of DLBS1033 on steady state group was 
8.6 hours. This result indicated that the effect 
as fibrinolytic could be measured after steady 
state condition was reached. The increase of 
PAP complex concentration level in 2 hours also 
showed that the absorption was relatively fast 
and it was ensured that the absorbed DLBS1033 
components were active form.12
The drug profile in steady state condition is 
important information for long term used drug. 
As an oral fibrinolytic drug, DLBS1033 can be 
used for long period in some clinical conditions, 
such as post cardiovascular events. One pilot 
study was conducted to evaluate the efficacy of 
oral lumbrokinase for stable angina pectoris. On 
that trial, ten subjects were given two tablets of 
250 mg oral lumbrokinase, three times daily, 
for 30 consecutive days. It is concluded that the 
drug could improve the myocardial perfusion in 
patients.15 This result needs to be extrapolated 
to the bigger trial with more subjects. In current 
clinical practice, DLBS1033 usually use as an 
adjuvant drug for standard treatment.
In our study, quantification of half-life used 
pharmacodynamics parameters, since the real 
elimination half-life of this drug is still unknown. 
The DLBS1033 half-life quantification could be 
more accurate if the concentration of DLBS1033 
protein fraction in plasma can be quantified.
CONCLUSION
On this study, we concluded that the 
fibrinolytic effects of DLBS1033 might be 
measured in steady state condition. The biological 
half-life of DLBS1033 in steady state condition 
was 8.6 hours. There were no serious adverse 
events on the two groups. Result of this study can 
be used as a reference to quantify dose regimen 
for the next clinical trial using this drug.
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